The recent withdrawal of rofecoxib (Vioxx) from the market has intensified controversy about the safety of cyclooxygenase (COX)-2 inhibitors. Results from several recently published studies address ...
Toronto, ON - A new retrospective cohort study has found no increase in the short-term risk of AMI among elderly users of COX-2 inhibitors, nor did it find any evidence of a cardioprotective effect of ...
Cyclooxygenase-2 (COX-2) inhibitors have long been employed to modulate inflammatory responses in a range of conditions, from arthritis to malignancies. In recent years, the convergence of ...
Ferroptosis plays an essential role in chronic liver diseases, and cyclooxygenase-2 (COX-2) affects liver fibrosis through multiple mechanisms. However, research on COX-2 regulation of ferroptosis in ...
UPSTREAM, DOWNSTREAM: Biochemical activity upstream of cyclooxygenase is better understood than reactions downstream of the enzyme. Cancer, Alzheimer's disease, and stroke represent disparate ...
NEW YORK, July 18 (Praxis Press) A new class of nonsteroidal anti-inflammatory drugs selectively inhibits cyclooxygenase (COX)-2 and may produce fewer adverse effects than nonselective inhibitors.
Augusta University has patented NSAID derivatives acting as prostaglandin G/H synthase 1 (PTGS1; COX-1) and/or COX-2 inhibitors potentially useful for the treatment of inflammation and pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results